Eurazeo’s Post

Pharmatest was excited to join the NK-ENGAGE consortium for a productive face-to-face meeting in Oslo! This ambitious Eurostars and Business Finland -funded R&D project is focused on creating an innovative synthetic small polypeptide for treating multiple myeloma (MM), as well as developing advanced preclinical models in the presence of human immune cells. We are proud to collaborate with a strong alliance of distinguished institutions and biotech firms, including Oncopeptides AB (publ) (Sweden), KTH Royal Institute of Technology in Stockholm, and Oslo University Hospital. The discussions we had were truly inspiring and highlighted the potential for groundbreaking advancements in MM therapy. Learn more about this exciting initiative here: https://lnkd.in/dwTtfQEi https://lnkd.in/dStH3MZR Eurostars is part of the European Partnership on Innovative SMEs. The partnership is co-funded by the European Union through Horizon Europe. #eurostars #multiplemyeloma #researchanddevelopment #preclinicalresearch

Today, we are thrilled to announce the successful closing of an oversubscribed Series B financing of $144M. This funding will propel the advancement of multiple programmed T cell product candidates to early clinical proof-of-concept in #ovariancancer and other #solidtumors, and further expand our pipeline and platform. We are also excited to welcome Jake Simson, PhD from RA Capital Management to our Board of Directors. Our lead program, OPB-101, is a mesothelin-specific CAR T cell enhanced by Outpace's proprietary technologies: OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™. OPB-101 has shown complete elimination of solid tumors in stringent in vivo models at very low treatment doses (as low as 50,000 cells) and is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. We extend our gratitude to our world-class syndicate of investors for believing in and supporting our mission to revolutionize treatment outcomes for #patients battling #solidtumors. Read more in our press release: https://lnkd.in/eimM3UZi The Series B financing brings our total capital raised to approximately $200 million and was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments (Alexandria Real Estate Equities, Inc.), and other undisclosed investors. Outpace’s existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation, Sahsen Ventures, LLC, also participated in the round. #proteindesign #celltherapy #oncology #solidtumors #AI #biotech #syntheticbiology #seattle #CAR #TCR 

Congrats to Outpace Bio for the latest funding round reaching ~$200M before entering the clinic. However, despite being a demonstration of high success and credibility of the team, we believe the model is hardly sustainable in the long run. We need to find ways to fund great ideas and smart teams on more modest budgets. We believe that decentralizing teams and expanding frontiers is a good starting point. This is the reason behind the Brazil's BEST™ cohort, a first selection of companies from the brazilian ecosystem that have global aspirations and great potential to test and generate disruptive treatments with capital efficiency. Just as an example, look at VYROBIO - with less than $10M (20X more efficient, in this case) in capital they are heading to the clinic to test their genetically engineered zika virus as and oncolytic therapy against glioblastoma in less than 4 years. Quite an achievement, if you ask me :) There are other companies following the same path and we believe there is a recipe here. We invite investors interested in discussing the topic to reach out and discuss this model. If you, RA Capital Management Qatar Investment Authority Surveyor Capital, @Sheatree Capital, Black Opal Ventures, @Alexandria Venture Investments ARTIS Ventures, Playground Global, Bristol Myers Squibb Abstract Ventures, Civilization Ventures, Mubadala Capital, @Breton Capital Ventures, Washington Research Foundation, Sahsen Ventures, LLC, are interested in discussing this, dont hesitate to reach out.

📢 We are very pleased to announce that our portfolio company iOnctura has closed a €80M Series B round, led by new investors Syncona Limited and the European Investment Council. This funding will support the late-stage development of treatments for multiple neglected and hard-to-treat cancers. Since our initial investment in 2019, iOnctura has shown exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat. Roginolisib will be tested in a broader patient population for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis. Cambritaxestat will be further developed for fibrotic cancers like metastatic pancreatic cancer. We're excited to welcome new investors and support iOnctura in advancing these critical treatments. #financing #oncology #drugdevelopment #cancertreatment #cancerresearch

Today is #WorldCancerDay dedicated to raising awareness about cancer and honoring those affected by the disease. It is the third and final year of the campaign 'Close the care gap', which calls on governments to take action to reduce inequities in accessing quality cancer care. Throughout this day, we are recognizing the groundbreaking medical innovations and progress by our portfolio companies in helping make cancer diagnosis and treatment more accurate >> IntraGel Therapeutics, Dio Tree, Barcode Nanotech, UB Therapeutics, Ark Surgical Ltd., MicroSteer Robotics and EMRIS Pharma. Find out more about their remarkable innovations at >> https://lnkd.in/dwHSYRMz Let's help create a future without cancer. 🇮🇱 Israeli tech, #nomatterwhat! #CancerAwareness #EarlyDetection #CloseTheCarGap

🚀 #EMIM 2024 Conference Launch Alert! 🚀 Join us at EMIM 2024 for our product launch! Stop by our booth to learn more and discuss your preclinical imaging needs. See you there! #EMIM2024 #ProductLaunch #PreclinicalImaging #pet #spect 🎉

Exciting times unfold in the German biotech scene, with familiar companies leading the charge. Rapid evolution fueled by robust investments, exceptional talent, and cutting-edge science catapults the industry onto the global stage. Germany's commitment to innovation has attracted significant investments, propelling it to the forefront of the international biotech arena. Recognizable names signify not only the strength of the German ecosystem but also its potential for global impact. This synergy of investment and talent has laid the foundation for a competitive and vibrant biotech landscape. From local recognition to global limelight, the success of German biotech is a testament to visionary investments and resilient minds. Cheers to the continued success and global influence of the German biotech industry! 🚀🌍🔍 #BiotechInnovation #GlobalImpact #GermanBiotechJourney

Just back from an exhilarating trip to Oslo, and I’m really energized. My colleagues and I had the honour of meeting with some of the brightest minds of the Norwegian life science community, and an evolving biotech startup scene. Thanks to the amazing folks at Oslo Science City we had the opportunity to explore new possibilities for partnerships and cooperation. We had the opportunity to delve into groundbreaking research in genetics and biopharmaceutical innovation like next generation cell therapy for cancer treatment, with key players at the Oslo University Hospital (OUH). The work they are doing focused on patients’ needs is inspiring. And it doesn't stop there! We were given a sneak peek into the future by the Universitetet i Oslo (UiO) | University of Oslo, showcasing their upcoming Life Science Center focusing on novel approaches for achieving precision medicines in Cardiovascular Research and Neuroscience – much aligned with our own R&D strategy. Finally, we had lunch in the iconic Munch room at the Oslo City Hall, exchanging ideas with Norwegian industry and academic leaders, all hosted by Anita Leirvik North, Oslo’s Vice Mayor for Culture and Business. I'm in awe of Oslo's rapidly growing life science ecosystem. The potential for groundbreaking advancements is enormous. My colleagues and I are honored and humbled by the opportunity to join vibrant discussions on current and future landscapes in this field. Reflecting on our journey since acquiring Algeta in 2014, the pioneer in developing Xofigo®, and witnessing Oslo’s dedication to life sciences, I’m more convinced than ever of the vast opportunities for collaboration and innovation. Let’s keep pushing boundaries – together we can make a difference! #TeamBayer #RD #Innovation #Research #lifescience #healthforall #OsloScienceCity #Legemiddelindustrien (LMI) #OsloCancerCluster

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

BAT-19 at the 11th LSBC Central European Life Science Investment Conference in Kraków I'm thrilled to announce that my biotech startup, BAT-19, is participating in a pitch session organized by the LSBC. Our innovative antiviral platform, designed to combat a wide range of infectious lung diseases, is vying for investor support and a coveted spot in the 2024 HICEE Start-up Support Program. I'm honored to be surrounded by prestigious institutions like the Francis Crick Institute, Dream Catcher Ventures, Cobin Angels, Ryvu Therapeutics, BioIn Med, NVIDIA, H Tree Capital, and Captor Therapeutics. Their presence underscores the potential of BAT-19 and my vision for BINOS™, a company dedicated to fostering scientific advancement in a more accessible and impactful way. My journey with BAT-19 has been a testament to the challenges and rewards of commercializing groundbreaking scientific projects. While I've come a long way, I believe that BINOS™ could have accelerated this process. As we continue to develop BAT-19, I'm excited to see where this journey takes us. My vision for BINOS™/Babu™ is to create a world-leading company that fosters scientific advancement through a more accessible and innovative approach. The challenges I've faced with my own commercial project, BAT-19, highlight the need for such a platform. Despite BAT-19's groundbreaking potential, the journey has been long and arduous. While we've made significant progress, I believe this road could have been much shorter and more efficient if BINOS™ had been there already! Link 1: https://shorturl.at/25ZmF